» Articles » PMID: 25519449

Most People with Long-duration Type 1 Diabetes in a Large Population-based Study Are Insulin Microsecretors

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2014 Dec 19
PMID 25519449
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Small studies using ultrasensitive C-peptide assays suggest endogenous insulin secretion is frequently detectable in patients with long-standing type 1 diabetes (T1D), but these studies do not use representative samples. We aimed to use the stimulated urine C-peptide-to-creatinine ratio (UCPCR) to assess C-peptide levels in a large cross-sectional, population-based study of patients with T1D.

Research Design And Methods: We recruited 924 patients from primary and secondary care in two U.K. centers who had a clinical diagnosis of T1D, were under 30 years of age when they received a diagnosis, and had a diabetes duration of >5 years. The median age at diagnosis was 11 years (interquartile range 6-17 years), and the duration of diabetes was 19 years (11-27 years). All provided a home postmeal UCPCR, which was measured using a Roche electrochemiluminescence assay.

Results: Eighty percent of patients (740 of 924 patients) had detectable endogenous C-peptide levels (UCPCR >0.001 nmol/mmol). Most patients (52%, 483 of 924 patients) had historically very low undetectable levels (UCPCR 0.0013-0.03 nmol/mmol); 8% of patients (70 of 924 patients) had a UCPCR ≥0.2 nmol/mmol, equivalent to serum levels associated with reduced complications and hypoglycemia. Absolute UCPCR levels fell with duration of disease. Age at diagnosis and duration of disease were independent predictors of C-peptide level in multivariate modeling.

Conclusions: This population-based study shows that the majority of long-duration T1D patients have detectable urine C-peptide levels. While the majority of patients are insulin microsecretors, some maintain clinically relevant endogenous insulin secretion for many years after the diagnosis of diabetes. Understanding this may lead to a better understanding of pathogenesis in T1D and open new possibilities for treatment.

Citing Articles

IFN-α Induces Heterogenous ROS Production in Human β-Cells.

Wagner L, Melnyk O, Turner A, Duffett B, Muralidharan C, Martinez-Irizarry M bioRxiv. 2025; .

PMID: 40027743 PMC: 11870469. DOI: 10.1101/2025.02.19.639120.


Detection of Insulin in Insulin-Deficient Islets of Patients with Type 1 Diabetes.

Krivova Y, Proshchina A, Otlyga D, Kharlamova A, Saveliev S Life (Basel). 2025; 15(1).

PMID: 39860066 PMC: 11766825. DOI: 10.3390/life15010125.


Immune perturbations in human pancreas lymphatic tissues prior to and after type 1 diabetes onset.

Golden G, Wu V, Hamilton J, Amses K, Shapiro M, Japp A bioRxiv. 2024; .

PMID: 39345402 PMC: 11429609. DOI: 10.1101/2024.04.23.590798.


Exploring pancreatic beta-cell subgroups and their connectivity.

Rutter G, Gresch A, Delgadillo Silva L, Benninger R Nat Metab. 2024; 6(11):2039-2053.

PMID: 39117960 DOI: 10.1038/s42255-024-01097-6.


Associations between diabetes-related genetic risk scores and residual beta cell function in type 1 diabetes: the GUTDM1 study.

Fuhri Snethlage C, Balvers M, Ferwerda B, Rampanelli E, de Groen P, Roep B Diabetologia. 2024; 67(9):1865-1876.

PMID: 38922416 PMC: 11410997. DOI: 10.1007/s00125-024-06204-6.


References
1.
Jones A, Hattersley A . The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013; 30(7):803-17. PMC: 3748788. DOI: 10.1111/dme.12159. View

2.
Dabelea D, Mayer-Davis E, Andrews J, Dolan L, Pihoker C, Hamman R . Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study. Diabetologia. 2012; 55(12):3359-68. PMC: 4492685. DOI: 10.1007/s00125-012-2719-6. View

3.
Lachin J, McGee P, Palmer J . Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes. 2013; 63(2):739-48. PMC: 3900540. DOI: 10.2337/db13-0881. View

4.
Besser R, Shields B, Casas R, Hattersley A, Ludvigsson J . Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care. 2012; 36(2):195-201. PMC: 3554273. DOI: 10.2337/dc12-0836. View

5.
Steffes M, Sibley S, Jackson M, Thomas W . Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003; 26(3):832-6. DOI: 10.2337/diacare.26.3.832. View